Madrigal Pharmaceuticals (MDGL) to Announce Quarterly Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Madrigal Pharmaceuticals to announce earnings of ($2.7735) per share and revenue of $349.3710 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, beating the consensus estimate of ($3.61) by $0.36. Madrigal Pharmaceuticals had a negative return on equity of 50.15% and a negative net margin of 27.32%.The company had revenue of $311.34 million during the quarter, compared to the consensus estimate of $301.05 million. During the same period last year, the firm earned ($3.32) earnings per share. The company’s revenue was up 126.8% on a year-over-year basis. On average, analysts expect Madrigal Pharmaceuticals to post $-7 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ MDGL opened at $537.58 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.16 and a current ratio of 3.50. Madrigal Pharmaceuticals has a 1 year low of $286.44 and a 1 year high of $615.00. The stock’s 50-day simple moving average is $515.62 and its 200-day simple moving average is $500.35. The firm has a market cap of $12.40 billion, a price-to-earnings ratio of -42.00 and a beta of -1.05.

Insider Buying and Selling

In related news, Director Richard S. Levy sold 5,682 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the sale, the director directly owned 22,015 shares of the company’s stock, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $495.74, for a total value of $516,561.08. Following the sale, the insider directly owned 10,033 shares in the company, valued at approximately $4,973,759.42. This represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,568 shares of company stock worth $3,880,711. 17.60% of the stock is currently owned by company insiders.

Institutional Trading of Madrigal Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. bought a new position in shares of Madrigal Pharmaceuticals in the 4th quarter worth about $39,000. Quarry LP bought a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at about $39,000. Johnson Financial Group Inc. acquired a new stake in Madrigal Pharmaceuticals during the third quarter worth about $50,000. Smartleaf Asset Management LLC raised its stake in Madrigal Pharmaceuticals by 50.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 63 shares during the period. Finally, Kestra Investment Management LLC bought a new position in Madrigal Pharmaceuticals in the second quarter worth about $85,000. Institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

MDGL has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. HC Wainwright reissued a “buy” rating and set a $620.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, May 6th. Truist Financial lifted their price target on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $687.93.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.